- Home
- Automated
- NDF A-Z listing
- Caspofungin
C
Caspofungin
Subsidy Information and Financing Scheme
No
Drug Guidance
Yes
Post-marketing information
No
Summary of Biologics
No
Active ingredient: Caspofungin
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
08/02/2023 Echinocandins for treating invasive candidiasis
The Ministry of Health’s Drug Advisory Committee has recommended:
Anidulafungin 100 mg injection
in line with its registered indications for treating invasive candidiasis in view of favourable clinical and cost-effectiveness compared with other echinocandins.
Funding status
[R] Anidulafungin 100 mg injection is recommended for inclusion on the MOH Standard Drug List (SDL) from 1 April 2023.
[NR] Subsidy does not apply to micafungin 50 mg injection or caspofungin 50 mg and 70 mg injections.
Legend
This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.
Legend list
Indicator | Legend |
|---|---|
R | Recommended for subsidy |
NR | Not recommended for subsidy |
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Drug availability
Formulation | Public Healthcare Institution |
|---|---|
Injection, Powder, For Solution 50 mg/vial |
|
Injection, Powder, For Solution 70 mg/vial |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Intravenous
FUPASCIN POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG/VIAL [SIN15687P]*
PERGILAS POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG/VIAL [SIN15857P]*
CASPOCAN POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50 MG/VIAL [SIN15697P]
DALVOCANS POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG/ VIAL [SIN15551P]*
FUPASCIN POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 70MG/VIAL [SIN15686P]*
PERGILAS POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 70MG/VIAL [SIN15856P]*
DALVOCANS POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 70MG/ VIAL [SIN15552P]*
CASPOVITAE POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG/VIAL [SIN15975P]
CASPOVITAE POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 70MG/VIAL [SIN15976P]
* The following products do not have any clinical information available